Expand all sections

Iopofosine I 131

Extended indication Treatment of patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymph
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Iopofosine I 131
Domain Hematology
Reason of inclusion New medicine (specialité)
Main indication CLL
Extended indication Treatment of patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy.
Manufacturer Cellectar
Budgetting framework Intermural (MSZ)
Additional remarks Fabrikant: Cellectar Biosciences

Registration

Registration route Centralised (EMA)
ATMP No
Submission date 2024
Expected Registration 2025
Registration phase Clinical trials
Additional remarks NCT02952508

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.